

AstraZeneca Pharmaceuticals Aktiebolag
SE-151 85 Södertälje, Sweden
T: +46 8 553 260 00
F: +46 8 553 290 00
astrazeneca.com

The Manager – Listing
BSE Limited
Corporate Relationship Department
P J Towers, Dalal Street
Fort, Mumbai 400 001

Date: 3 April 2017

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra - Kurla Complex
Mumbai – 400 051

Dear Sirs,

Sub: Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Please find enclosed the relevant disclosure required to be made by the Promoter (AstraZeneca Pharmaceuticals AB, Sweden) in terms of the requirements of Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, with regard to equity shares of AstraZeneca Pharma India Limited, held by the promoter, as on March 31, 2017.

Please take note of the above and acknowledge receipt.

Thanking you,

Yours faithfully,
for **AstraZeneca Pharmaceuticals AB**



Yvonne Bertlin
Director


CC: The Company Secretary & Legal Counsel,
AstraZeneca Pharma India Limited,
Block N1, 12th Floor
Manyata Embassy Business Park
Rachenahalli, Outer Ring Road
Bangalore – 560045
India

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	AstraZeneca Pharma India Limited		
2.	Name(s) of the stock exchange(s) where the shares of the TC are listed	a) BSE Limited b) National Stock Exchange of India Limited		
3.	Particulars of the shareholder(s): a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Names of promoter(s), member of the promoter group and PAC with him.	None AstraZeneca Pharmaceuticals AB, Sweden		
4.	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share / voting capital where applicable	% of total diluted share/voting capital of TC (*)
	As of March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC	18,750,000 - - - -	75.00% - - - -	Not applicable since there are no outstanding convertible securities / warrants
	Total	18,750,000	75.00 %	

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For **AstraZeneca Pharmaceuticals AB**



Yvonne Bertlin
Authorized Signatory

Place: Sweden
Date : 3 April 2017